Article Versions Notes

Ravindranath MH, Ravindranath NM, El Hilali F, Selvan SR, Filippone EJ. Ramifications of the HLA-I Allelic Reactivity of Anti-HLA-E*01:01 and Anti-HLA-E*01:03 Heavy Chain Monoclonal Antibodies in Comparison with Anti-HLA-I IgG Reactivity in Non-Alloimmunized Males, Melanoma-Vaccine Recipients, and End-Stage Renal Disease Patients. Antibodies. 2022; 11(1):18. https://doi.org/10.3390/antib11010018

Ravindranath, Mepur H., Narendranath M. Ravindranath, Fatiha El Hilali, Senthamil R. Selvan, and Edward J. Filippone. 2022. "Ramifications of the HLA-I Allelic Reactivity of Anti-HLA-E*01:01 and Anti-HLA-E*01:03 Heavy Chain Monoclonal Antibodies in Comparison with Anti-HLA-I IgG Reactivity in Non-Alloimmunized Males, Melanoma-Vaccine Recipients, and End-Stage Renal Disease Patients" Antibodies 11, no. 1: 18. https://doi.org/10.3390/antib11010018

Ravindranath, M. H., Ravindranath, N. M., El Hilali, F., Selvan, S. R., & Filippone, E. J. (2022). Ramifications of the HLA-I Allelic Reactivity of Anti-HLA-E*01:01 and Anti-HLA-E*01:03 Heavy Chain Monoclonal Antibodies in Comparison with Anti-HLA-I IgG Reactivity in Non-Alloimmunized Males, Melanoma-Vaccine Recipients, and End-Stage Renal Disease Patients. Antibodies, 11(1), 18. https://doi.org/10.3390/antib11010018